Startups 

We aim to substantially improve health outcomes in two large and rapidly growing patient populations: (1) patients with combined heart failure (HF) and diabetes, and (2) individuals with insulin resistance, including prediabetes and metabolic syndrome. These conditions frequently coexist, mutually exacerbate disease progression, and account for a disproportionate share of morbidity, mortality, and healthcare costs. 

Our approach is based on the discovery of a novel protein that directly impairs glucose uptake in myocardial cells and likely in other tissues. Its biological function is unique and fundamentally distinct from known metabolic regulators, and its therapeutic application has been patented. Building on this discovery, we are developing a first-in-class drug that selectively inhibits this protein, targeting a previously unexplored mechanism underlying both cardiac dysfunction and insulin resistance.

By restoring myocardial glucose uptake, this therapy is expected to improve cardiac efficiency and function, leading to fewer episodes of decompensated heart failure and reduced hospital admissions. In parallel, improved systemic insulin sensitivity may delay or prevent the development and progression of cardiovascular disease in a large, high-risk population, potentially before irreversible organ damage occurs.